Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A recent post of yours B.O.B. stated that after your research this is your top pick of possible COVID plays. Sure, there are huge efforts in work and strong headwinds to accomplish these targets. The teams under the CEO seem to be also striving toward our success. Success raises all boats on this tide. Without the COVID influences this process would have been much tougher and longer. Maybe improbable. This small company has hold of possible science for treatments that no other company is pursuing. CEO Monreau recently explained the importance of our control over Ifenprodil and the lapsed patents. This control was almost his main point beside trying to address the issues of actually getting trial sites due to countries recovering and influences of Big pharma wanting their drugs tested in already sponsored institutions. We are not a pump concept and have actual science to sell. Many huge pharmas wish they had such promising science, IMHFO. Yes we struggle now but I too have not found such promising science at ANY BIO/Pharma I've followed since the start of the Pandemic...GLTA...
Ifenprodil has decent Simple science behind the application and will be tested without having "Pre" inside/political support.
The drug Ifenprodil does not have a questionable development, actually may work and has a good safety record...JMHO... A reply to B.O.B. was intended. Thanks for asking...GLTA...
Colonoquin is harmful and not supported by FDA for treatment of Covid. Remdesivir was made during the research at Wouhan China/escape of Covid-19 and is barely effective. Both have presidential support and pumping. Seems to set a low bar for something with actual benefits and low dangers. All IMHO...GLTA...
The Virus has spread here in the US and the current means of treatment are inadequate for the number of patients. The Gov is throwing money at the wall and hoping it will stick somewhere. Action. Masks anyone?
The first companies to produce relevant positive data will receive similar or larger recognition. JMHO...GLTA...
Nice interviews with a dash of news. I didn't expect any real news, as they (AGN) will probably "halt" again for that, I hope -LOL. Sure there is alot of competition for patients by Big Pharma and connecting with the right institutions is difficult. The increased scientific data behind Ifenprodil should help move these enrollments faster.
The long term issues are our target with IPF and few drugs help that...GLTA...
https://www.fox8live.com/2020/07/27/covid-leaves-lasting-impacts-lung-functioning/
The only win and hope is that the Court handle UCANN just like any other BK and not punish us by identifying UCANN with the THC angle.
Must have pissed off PPlacement folks to end in BK. Company has been run crazy since his S American jungle drugs thing with that Dr. Guess he never came down...
F*kt up an easy future for us. Look at Valdesa with Tony.
The article is a month old and I'm hopeful...GLTA...
Investigator-led COVID-19 study in South Korea
One research site was initiated at the end of May, 2020, and two sites were initiated in early June for the investigator-led COVID-19 phase 2 trial in South Korea. Dr. Dong Sik Jung, professor, in the division of infectious disease of Dong-A University Hospital, has now begun the process of screening patients.
https://www.stockwatch.com/News/Item?bid=Z-C%3AAGN-2925712&symbol=AGN®ion=C
Research institutions
I'm disappointed with SK's results thru Novotech too. Expected completed research as planned. SKoreans are usually very prompt and take responsibilities for plans and promises. I feel we may still see results even at these late dates.
Novotech and GVI apparently have the contacts for patients in many of the hot spots for COVID. I feel the initial IPF trial should fill fast too and cant see any reason for delays awaiting countries or states where enrollments may be slow.
With the building science from sources to back Dr William's research there should be plenty of impetus to be moving ASAP...
Good stuff, CEO continuing to publicize the most recent news and has more to come. Also science will eventually be recognized and prevail, that's what I get from the last couple days news, IMO. Thanks to all posters.
I noticed that Dr William G North was pitching a Clinical Trial for Ifenprodil's effectiveness on the NDMA issues of Lung cancer. IMO...
Looks like it took our money, thru AGN's CEO Monroeu, with confirming science by Dr Williams, to get this whole New concept of Ifenprodil's NMDA effect in the LUNGS to clinical trial.
I would hope Dr Williams has a chance to see Dr North's work...
I feel More confident Daily, JTHC'sO...GLTA...
The singing is done, and she dropped the mic.
Thanks for posting this DD. The steady progress in the Clinical Trials and news supporting the NDMA science has made this happen. IMO, Great news. Looks like the remaining few will want to cover asap?.. Playing with fire here for pennies, literally.
We need a shocker from Novotech and/or GVI re;AGN...>>>
"The friendly competition", CM. 7/19...GLTA...
I would say broad Vaccine availability would be hard to achieve and implement to the populace. That Ifenprodil may be the 'treatment' for millions of already infected and those suffering lung damage and that the way it works is different than other IPF/CC/ALI treatments 'I' have seen. etc.
The knowledge from NASH morphed into the AGN concepts and has thoughtful scientific R+D along with strong leadership and a big company's visions. IMO. AGN's other 'pipeline' drugs, with their repurposed science, also are to be tested eventually too. People have posted about Kidney issues from COVID and the possible relevance of AGN's drugs.
Licensing and partnerships await any company with 'near term' Proven COVID associated successes. IMO. Maybe even 'Fast Track' status thru the USFDA, grants.
Not to mention the - CKD - IBD future is separate from COVID/IPF/CC/ALI, which I just did. LOL.
From here - AGN - we can see crystal ball possibilities, IMO...GLTA...
My opinion is that we all have a "Right" to differing opinions and we should enjoy some 'inter-squad' rivalry, joviality and bloviating...GLTA...
Getting killed by 'friendly fire' is terrible and much worse when it is also an abuse of authority and the worst when it is malicious.
Posted this in conflict with the post saying BTH to NASH/AGN happened in 2016? Happened 8-18.
We got our Phase 2 Trials ++, although the wait and patience needed has been almost unbearable. Kal and the F+Fs have certainly done much better than the common shareholders thru this all. To think I was buying these $.25+ BTH shares (Blo profits) to support the pps back then and yet held most thru the manifestations to finally arrive here with some other Longs. I had thought the new Ideas continued to have merit/possibilities even as the BTH languished, so Long time Longs may yet be well rewarded. Glad I held most and have tripled my bets at these comparatively low prices...
AMG/shell3/smoki/geo/Jag/etc, thanks for the discussions, DD, arguments and opinions...GLTA...
I still think it doesnt matter, they've got the shares already as I posted recently. Hope someone can prove that info wrong.
The Voraxail separator appears to be dead. MAYBE they are actually making face shields, we can only hope they can find a demand for them in Florida.
Messing up these weak company plans will just make this go BK. IMO, a guaranteed loss.
I voted for 1 year shareholder review and every year.
BTW, the 8000 model that was used at the Google competition (failure*) for oil cleanup never was sold?? Probably parted it out as scrap metal.
* turned out to being the Xfer pump motor phasing was reversed, just swap 2 phase wires to correct.
https://www.stockwatch.com/News/Item?bid=Z-C%3AAGN-2925712&symbol=AGN®ion=C
Research institutions
The company is working with five study sites in the U.S. and has completed all site selection visits and is working to finalize all contract negotiations. The company has also received approval from a central institutional review board that applies to all sites. The states where the institutions are located include Florida, Illinois, Missouri and Ohio.
The company has also signed agreements with two research sites in Australia and one in Romania. Ethics approval for the study has been submitted in Australia and will be submitted for Romania and the Philippines shortly.
Investigator-led COVID-19 study in South Korea
One research site was initiated at the end of May, 2020, and two sites were initiated in early June for the investigator-led COVID-19 phase 2 trial in South Korea. Dr. Dong Sik Jung, professor, in the division of infectious disease of Dong-A University Hospital, has now begun the process of screening patients.
ifenprodil manufacturing
The company retained Cascade Chemistry, a U.S.-based contract research organization specializing in chemical synthesis, to scale up cGMP (current good manufacturing practice) manufacturing of ifenprodil.
The company requires the active pharmaceutical ingredient (API) of ifenprodil in order to develop new formulations of the drug including an injectable and a slow release tablet. Cascade is nearing completion of its first engineering run of API with the cGMP synthesis to begin shortly.
The company is also working with the U.S. FDA on its plans to have finished product of ifenprodil manufactured and available in as short a time frame period as possible, should the phase 2b/3 trial achieve positive results.
Cash position
The company currently has an approximate cash balance of $7.5-million. The company believes the funds on hand will be sufficient to cover the costs of the company's phase 2 IPF and chronic cough study, the cost of supporting the investigator-led phase 2 COVID-19 study in South Korea and the multinational phase 2b/3 COVID study, to their full conclusion, including all general operating expenses.!!!!!!!!!!!!!!!!!!!!!!!!!!
SKorea Ifenprodil manufacturing w/AGN?
https://adisinsight.springer.com/drugs/800055643
...GLTA...
Green news continues to accumulate with AGN. Old BTH holders still have a ways to go and these current shares are comparatively cheep. Ifenprodil science will be tested and I am investing and hope for strong results...GLTA...
We dont run the company, we can just buy, hold or sell the stock hopefully on foresight, hindsight is less desirable.
BTW, salaries are pretty low with the stock compensation plans in effect. As noted other micros are doing a couple hundred M PPs. Our CROs are even INVESTED...
I'll make it a point to get Lucky tonight...
The proxy shows M Sadhra @ 263907 and C Moreau @ 900K ?
Jag had set his pump price @ 30 dolla, but had apparently changed minds and sold at the lows. Last Nov - Dec I sold some for taxes @$.04-5 and bought them back @$.07 to $.17 during that first COVID news. But those were BTH shares.
Been buying more recently as posted. Plenty of room for mistakes and Luck. I've had 2 long term OTC stocks go BK during this COVID S*t.
So...
I think that Recruitments will proceed fast for COVID with both starting as stated by August. SKorea delays are priced in even if there is news that it is being canceled, BUT MAY surprise us positively, IMO. AGN still has a portfolio of CKD - IBD - NASH drugs besides Ifenprodil.
My Point, IDK...GLTA...
Field Sobriety tests by an Officer at initial stop and then call in for a specially trained Officer or Lead Officer, almost always at least have another Officer involved. Officers can arrest under clear FS test results but if there is a passenger or uncooperative driver or possible altercation, policy is to keep contact with dispatch and wait for another Officer and Transport. Then the driver can accept a Blood test there or refuse. BAC devices are not being used currently. Other areas may differ... From Sgt Jim...
Geo was just posting info he wanted to contribute. IMHFO.
Reply to Shaggy?
I'm still out just watching for BLO to move to Medical FAIMS/COVID, this might have soared again like during the Canada legalization spike. Kal could have helped both BTH/AGN and BLO. But.
THC / BAC is still an issue, but some form of breath - mouthpiece - safety of the 'devices' is what is needed Now. Blow into a balloon then put it thru their device?...GLTA...
Are they still getting paid? Are their facilities running? What is left for shareholders? Can they run under BK? Sad when a normal restructure BK is what we are hoping for...
128
order Approve Tue 07/14 1:40 PM
Order Establishing Interim Compensation Procedures .
Related: [-] 47 Motion to Approve
129
misc Document/Support Document Wed 07/15 10:32 AM
Periodic Report Regarding Value, Operations, and Profitability of Entities in Which the Debtor's Estate Holds a Substantial or Controlling Interest Filed by Lindsay Riley on behalf of United Cannabis Corporation. (Riley, Lindsay)
WOW, that was easy and fast...They must be working OT... I had to edit the .* but youall can go to the ClinicalTrials web site, look her info up under the 'Contact' section and confirm... She was nice enough to reply and I asked for permission to post the answer. Copy follows...
Thank You, Dr Mark and CEO Cris...GLTA...
Hi TCM:
Yes, I can confirm we are working with Algernon on both the AGN120-2 and AGN120-3 trials.
Nancy
Nancy Stewart, Ph.D.
Senior Scientific Manager/gvicds
Clinical Development Solutions
4-1250 Waverley St. Winnipeg MB CANADA R3T 6C6
Email: nstewart-gvicds
-----Original Message-----
From: tc
Sent: July 13, 2020 7:09 PM
To: Nancy Stewart nstewart-gvicds
Subject: Clinical Trial for Ifenprodil
Hello Dr Stewart
I am a long time invertor in Algernon Pharma. I am using the link from the CC site. I have watched the CEO, Chris Monroe discuss working with GVI on the COVID / Ifenprodil Clinical Trial. Just want to confirm this, no inside info. I may post a positive reply with permission.
I would really like just a link to a public statement, if possible. IMO, it will be Great to have the assistance...
Thank You
TCM
Sorry for you that you cant see this under the 'Contact' header with phone #, there in Black and white. Call her and tell us what she says. Page down past the eligible stuff.
I TRUST that they're involved.
I, at least, also am sure that Everything going on is Not being said. Drs Chris and Mark just might be busy on something they consider more important. Good for them...and us... I ass-ume you called and 'expressed' your opinion of what they are doing wrong.
Maybe Gilliad has a PR dept and 'contact' page where questions are (also Not fully) answered. This is the OTC and we are lucky, IMHFO, to be invested in this Stock that May be significant. 1 in 100 OTC stocks actually fully succeed, this one Now Might, IMHFO.
'nitpicking'?.Hmmm....
"We don't run the companies, we can just Buy-Hold-Sell their Stock on foresight. Hind sight is less desirable"
contacts.
Nancy Stewart PHD, GVICDS, has been on the trial site here since before it was updated July 09 2020...
"Google"
Clinical Development Solutions
www.gvicds.com
Services include Strategy Development, Project Management, Clinical Trials, Regulatory Affairs, Quality Assurance, Pharmacovigilance and Scientific Writing. The aim at CDS is to help our clients get their products to market by the least expensive and fastest route while ensuring safety and integrity in medical product development.
https://clinicaltrials.gov/ct2/show/NCT04382924?term=Ifenprodil&cond=COVID&draw=2&rank=1
No need for anyone to dissect my simple posts. My discussion points were intended to stimulate others to glean the DD done on this forum. Research and/or DD has been posted and IF this message Board is NOT dominated or overfilled by a poster opinions' or nit-picking, that info can be found AND evaluated by individuals interested. I limit my responses, and look for new DD to post.
I dont know in what world Clinical Trials instantly are approved / then move directly to enrollment and dossing in ANY faster time frame than is being done here. This is NOT a huge pharma with unlimited resources and is doing very well coordinating the progress of the Repurposed drug concept, much better than anticipated before COVID. Our investments in AGN will have a very Fair chance of success. IMO.
AGN is not a Gilliad / that developed the disease and then the cure and then is pumped for bland successes. AGN has to show real successes and faces skepticism Cloroquin and Rendesevir (sp) can try to Buy-off.
BTW, Thanks Smoki for your efforts to post new articles. Some of us have been here a long time and retain positive attitudes...
"Old blind Pigs find the Truffles others miss."
"We don't run the companies, we can just Buy-Hold-Sell their Stock on foresight. Hind sight is less desirable"
Yes selling the BTH FAIMS proprietary research to BLO was discussed. Also due to SK's success in the COVID fight there is a delay but it appears Novotech, our CRO, is working on that AWAP. They are in process of recruiting the IPF / CC trials which were the original target of NP-120 before COVID.
COVID is Rampant in much of the US and we have a separate CRO coordinating the N America arm of the Multinational trial2b/3. Novotech is working in the Philippines and Dr, Mark has contacts in E Eu... 2b/3 trials have a good momentum, IMO.
Really, this is an OTC stock with a checkered history. Long time shareholders may be rewarded as well as newcomers. Everyone should decide their own Risk to Reward ratio, IMO. Plenty of new DD has been posted, I suggest reading the whole Lancet article for perspective on IPF/CC/COVID and where we might fit in...GLTA...
I am posting some research you made and this quote which implies that Ifeprodil affects the inflammation issues, described in the recent article I posted from the Lancet, that current IPF drugs do not address.
Your respected opinions would help refine this...
""And like I said before, HERE IS HOW OUR DRUG WORKS
Coronavirus infection induces increased production of proinflammatory cytokines and neuronal degeneration as a consequence of glutamate excitotoxicity. In physiological conditions, glutamate is mainly synthesized by neurons and released in the synaptic cleft as the primary excitatory neurotransmitter of the CNS that activates the ligand-dependant receptor AMPAr, which allows the entry of sodium ions and the passage of the nerve impulse in the post-synaptic neuron, leading to activation of the NMDA receptor (N-methyl-D-aspartate receptor) that allows the entry of calcium ions. During infection of neurons by coronavirus, cells detect the presence of virus and produce pro-inflammatory cytokines (TNF-alpha, IL-1 beta and IL-6) that down-regulate the astrocytic receptor GLT-1 (glutamate transporter 1) and prevent the efficient recapture of glutamate. This situation disturbs the regulation of glutamate homeostasis and theexcess of this neurotransmitter in the synaptic cleft leads to excitotoxicity associated with a massive entry of calcium which eventually leads to degeneration of and death of neuronal cells.""
Quote..." If antifibrotic therapy is to have a role, it is likely to take the form of inclusion in combination regimens, once effective anti-inflammatory treatments have been identified. Combination therapy could, in principle, address major anti-inflammatory and antifibrotic pathways while attenuating their fibrotic consequences."
S. Korea, "Yonhap", has posted this article about hospitalization rates there and most common symptoms. Easier to read and to the point.
"Of the total COVID-19 patients, 5,570, or 62 percent, were admitted to hospitals while 3,230 were admitted to community treatment centers dedicated to care of COVID-19 patients with mild or no symptoms.
The findings showed that 41.8 percent of the admitted COVID-19 patients experienced cough, followed by 28.9 percent with strong cough and 20.2 percent with fever."
https://en.yna.co.kr/view/AEN20200708008000320?section=science/medicine
This article talks about existing IPF drugs and their deficiencies. It sounds to me like NP-120 compounds are targeting some of the issues described here. Maybe someone qualified could comment. 2 months old but informative about IPF / COVID etc...
" However, this hypothesis must be advanced with important caveats, all of which need to be addressed if existing antifibrotic agents are to be applied in the current pandemic.
dysregulation of SARS-CoV-2 infection, nor can they be expected to attenuate the prothrombotic aspects of this complex pathogenic process. If antifibrotic therapy is to have a role, it is likely to take the form of inclusion in combination regimens, once effective anti-inflammatory treatments have been identified. Combination therapy could, in principle, address major anti-inflammatory and antifibrotic pathways while attenuating their fibrotic consequences.
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30225-3/fulltext
I wouldn't be surprised if they claim their going after COVID at some point.
That will bring them full circle with the FAIMS and reclaim the Breeathtec medical angle they tossed out at Algernon.
"" Of course, maybe an intercompany deal swapping some on the back shelf research stuff for some imagined 'on the Books' cash, then PR for months / years. Maybe Dr Yost would be called back to assist the/His medical angle and COVID too"". Easier than THC...
I see it coming from miles away. ""HMMM"'
So yeah...it's a great company to flip based on the tried and true pattern.
""Yes there were great runs, $.50- to $3.+ for BLO and $.07 to $.35+ for BTH, during the initial Canada Pot legalization thingee"".
Looks to me like we have a real chance here at AGN, IMHFO... Waiting for progress reports on several Actual, Real Time, Significant, World Wide developing company initiatives...GLTA...
Nice to see a PR finally. Gave us all a chance to buy a few more shares over the last few trade days. Lets hope recruitment is fast with this Short trial and then quick results...
Great...
Sharp eyes, cant believe we all missed this. Seems to indicate real movements in Canada and with the USFDA already 'in work'. Fills in this question about CRO work for AGN investors.
We know the Philippines, Australia will be managed by Novotech, Canada and USFDA by GVI which leaves E Eu/Romania for the Multinational Trials. Dr Williams may have those connections in work too.
Sad for Bellus's not reaching their statistical goal but this leaves the "NDMA receptor antagonist(?)" affected with Ifenprodil as a key research target. Good for AGN, IMO.
I doubt we will hear updates from this June 11 news or the efforts these two CROs' do. But the ducks should be lined up soon now, IMO...
Maybe the international contributions and recruitments of sites and patients will go much faster for AGN's Multinational Trials now than was thought before you pointed out the Canadian CRO, GVI was handling North America...
Novotech also works with India, another country suffering this later phase of infections. Maybe?. Didn't Dr Wiliams say he had made an Ethics presentation and concept thesis that they could present to prospect hospitals / Countries?...
Post 10342 IS directed at me...Answered.
Nothing I posted is incorrect. There apparently was confusion by Bayst of my post and the facts on the Clinical Trials.
Take a break yourself and adjust your attitude. Dude.
I am an old Crpl (Dis-Ret) and certainly not a dude. History and truth are not an Abyss, which is where AGN was. It now MAY HAVE real world significance, IMHFO...
Being a poor old Crpl (not really rich as some claim) I am buying this Speculative stock in increments and discussing My DD. I will work around a core holding.
Of course anyone is Free to disagree about my Facts or opinions and express their own, in This, My America. Your welcome for My Service to Defend OUR Rights.
"We don't run the companies, we can just Buy-Hold-Sell their Stock on foresight. Hind sight is less desirable"
I dont think SK CRIS or MOHW would allow itself to be used as a pump. This is a COVID trial. Ethics were approved yet patients were becoming few. I believe they still will produce results, just not in the expected time frame.
My reading is that the current IPF / CC Phase 2 Trial being recruited in Australia/NZ is different and separate from the planned Phase 2b / 3 Multinational Trials.
Canada Will be involved, probably in a lead roll IMO, along with the USFDA for sure,. Novotech can bring Patients from the Philippines or other Asian/Pacific countries and as noted has offices worldwide and in the US. Dont know about their reach to S America, Brazil.
I noted that Dr Williams had connections to E Eu that were discussed as part of his portion of the original BTH/AGN deal.
My reply is my interpretation and speculations.
https://clinicaltrials.gov/ct2/results?cond=&term=Ifenprodil&cntry=&state=&city=&dist=
May I reply.
They need S K or Ausie* to show reasonable successes for strong leverage going forward with the 2b/3 trials. Possible grants and opportunities along with a higher PPS.
Until then and Right now using the help of past connections in E Eu and Novotech where ever to get this moving seems pretty logical.
This is not just 2 guys but several teams led by 2 guys. They mention this in their videos.
JMO, please comment.
* Paid for thru Novotech with PP from Nov 19
"We don't run the companies, we can just Buy-Hold-Sell their Stock on foresight. Hind sight is less desirable"
"Pennyland is filled with storytelling companies." HMMmmm? I've owned several/many...
This one has Ethics Approvals for Clinical Trials from several countries including the USFDA, S korea, Australia, NZ and Canada so far, and is recruiting for a Phase 2 Trial Now.
No Crystal Ball theory, it's in Black and White. Reality stuff.
You don't hold any BLO stock. Got it. Sorry my Bad... I dont either anymore for the reasons I stated...
Maybe another explanation is that Novotech has offices in the Philippines along with many other countries. They kinda owe us for the S Korea delay and are investors in AGN anyway. It makes sense that their connections there be used, to me anyway.
Dr Mark Williams has worked in Eastern Europe and was / is planning Trials there for NASH/AGN, involving CKD and IBD things. Part of the initial reverse merger reason this is now AGN. Those Drugs have obviously taken a back seat right now but there are already connections over there, IMO.
Stuff pr'ed long ago when there was no COVID.
The currently recruiting Aussie / NZ Phase 2 Trials for IPF / CC were set up long ago too, through Novotech. These Trials seem to be relevant to COVID but are totally separate...JMO...GLTA...
Sure hope you took some profits here during that time. Breathalyzers may be tough to sell for a while, IMO. FAIMS breath analysis is now in the past.?. Certainly the sister has changed direction.